Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Intrathecal immunoglobulin G (IgG) synthesis, cerebrospinal fluid (CSF) oligoclonal IgG bands and lesional IgG deposition are seminal features of multiple sclerosis (MS) disease pathology. Both the specific targets and pathogenic effects of MS antibodies remain poorly characterized. We produced IgG1 monoclonal recombinant antibodies (rAbs) from clonally-expanded plasmablasts recovered from MS patient CSF. Among these were a subset of myelin-specific MS rAbs. We examined their immunoreactivity to mouse organotypic cerebellar slices by live binding and evaluated tissue injury in the presence and absence of human complement. Demyelination, glial and neuronal viability, and complement pathway activation were assayed by immunofluorescence microscopy and compared to the effects of an aquaporin-4 water channel (AQP4)-specific rAb derived from a neuromyelitis optica (NMO) patient. MS myelin-specific rAbs bound to discrete surface domains on oligodendrocyte processes and myelinating axons. Myelin-specific MS rAbs initiated complement-dependent cytotoxicity to oligodendrocytes and induced rapid demyelination. Demyelination was accompanied by increased microglia activation; however, the morphology and survival of astrocytes, oligodendrocyte progenitors and neurons remained unaffected. In contrast, NMO AQP4-specific rAb initiated complement-dependent astrocyte damage, followed by sequential loss of oligodendrocytes, demyelination, microglia activation and neuronal death. Myelin-specific MS antibodies cause oligodendrocyte loss and demyelination in organotypic cerebellar slices, which are distinct from AQP4-targeted pathology, and display seminal features of active MS lesions. Myelin-specific antibodies may play an active role in MS lesion formation through complement-dependent mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021 · cited 1×
“The results of autologous hematopoietic stem cell transplantation (AHSCT) [19] and therapeutic B cell depletion [8] have called into question the role of antibody in MS lesion formation, despite numerous examples of Fig.”
BackgroundMicroglia development and function
Nayak, D., Roth, T. L., & McGavern, D. B. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120240 · Cited by 1,154
Regulation of oligodendrocyte differentiation and myelination
Emery, B. (2010) · Science · doi:10.1126/science.1190927 · Cited by 653
Control of local protein synthesis and initial events in myelination by action potentials
Wake, H., Lee, P. R., & Fields, R. D. (2011) · Science · doi:10.1126/science.1206998 · Cited by 636 · cited 1×
“and neurons on oligodendrocytes through glia-glia [12, 17] and axon-glia interactions [6, 7, 31] has been well documented.”
BackgroundTreatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Self-citationThe benefits and detriments of macrophages/microglia in models of multiple sclerosis
Rawji, K. S., & Yong, V. W. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/948976 · Cited by 217 · cited 1×
“Even with extended treatment, the morphology and survival of astrocytes and neurons remained unaffected in slices treated with MS#30 +HC, suggesting that early microglial activation may offer a protective or beneficial effect [27].”
BackgroundOligodendrocytes and the early multiple sclerosis lesion
Prineas, J. W., & Parratt, J. D. E. (2012) · Annals of Neurology · doi:10.1002/ana.23634 · Cited by 149
Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica
Liu, Y., Harlow, D. E., Given, K. S., Owens, G. P., Macklin, W. B., & Bennett, J. L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0767-4 · Cited by 17 · cited 7×
“Also, approximately 50% of NG2+ Olig2+ oligodendrocyte precursors were lost in slices by 24 h after treatment with NMO #53 +HC [14].”
BackgroundResultInfluentialSelf-citation
Cited by
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
Bennett, J. L., Costello, F., Chen, J. J., Petzold, A., Biousse, V., Newman, N. J., & Galetta, S. L. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00187-9 · Cited by 226
Self-citationMicroglial NLRP3 inflammasome activation in multiple sclerosis
(2020) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2019.08.007 · Cited by 83
Effect of CSF1R inhibitor on glial cells population and remyelination in the cuprizone model
Tahmasebi, F., Barati, S., & Kashani, I. R. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102179 · Cited by 17
Metadata
- Authors
- Liu, Y., Given, K. S., Harlow, D. E., Matschulat, A. M., Macklin, W. B., Bennett, J. L., & Owens, G. P.
- Venue
- Acta Neuropathologica Communications
- Published
- 2017-03-24
- Volume
- 5
- Issue
- 1
- Pages
- 25-25
- ISSN
- 2051-5960 (ISSN-L)
- OpenAlex
- W2600133287
- Cited by
- 69
- References
- 8
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. https://app.cochat.ai/papers/10.1186/s40478-017-0428-6
- The paper
- Liu, Y., Given, K. S., Harlow, D. E., Matschulat, A. M., Macklin, W. B., Bennett, J. L., & Owens, G. P. (2017). Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-017-0428-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.